Montelukast Sodium Market Size, Share, Growth, Trends, and Global Industry Analysis: By Dosage Form (Tablets, Oral Solutions, Simple Pills, Chewable Pills, Powder, and Others), By Indication (Asthma, Allergic Rhinitis, Urticaria, and Others), By Product (Crystal-like and Form-less/Amorphous), and By Region (North America, Europe, Asia Pacific, Latin America, and MEA), and Region Forecast 2019-2030.

 Montelukast Sodium Market size was valued at US$ 4,373.6 million in 2023 and is grow at 6.1% CAGR from 2024 to 2030. The montelukast sodium is a medication primarily used for the treatment of asthma and allergic rhinitis. It belongs to a class of drugs known as leukotriene receptor antagonists, which work by blocking the action of leukotrienes, substances in the body that contribute to inflammation, bronchoconstriction and other symptoms associated with asthma and allergies. The market for montelukast sodium includes both brand-name and generic versions of the medication, with various pharmaceutical companies producing and distributing it worldwide. In April 2022, scientists at the Indian Institute of Science in Bengaluru conducted a study that revealed that montelukast has the potential to stop COVID variants from replicating within the body of the infected. Thus, the studied market has been significantly impacted by the COVID-19 pandemic.

Moreover, the latest research on new montelukast treatment approaches is expected to drive the market in the coming years. The major factor attributing to the growth of the market is the increasing prevalence of diseases like asthma, allergic rhinitis, exercise-induced bronchospasm, primary dysmenorrhea, and urticaria. and rise in the geriatric population. Furthermore, in 2021, the Asthma and Allergy Foundation of America (AAFA) reported that each year, anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits, and more than 50 million people in the United States experience various types of allergies.

However, side effects with the product, such as stomach pain, heartburn, upset stomach, nausea, and diarrhoea may turn patients aversive toward consumption of montelukast and can cripple its overall market. Additionally, regulatory agencies have issued warnings and required updated labelling to reflect these safety concerns. Addressing these safety issues, conducting further research to understand the risks better, and implementing risk mitigation strategies present challenges for manufacturers in maintaining consumer confidence and regulatory compliance while ensuring the continued availability of montelukast sodium in the market.

Montelukast Sodium Market Key Developments

• In March 2021, Valeo Pharma Inc. entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two asthma therapies, Enerzair Breezhaler, glycopyrronium, and mometasone furoate and Atectura Breezhaler.
• In May 2021, montelukast Sodium was included in the Health Choice Arizona Formulary / Preferred Drug List. A Formulary / Preferred Drug List (PDL) is a list of drugs chosen by Health Choice Arizona and a team of doctors and pharmacists. Health Choice will cover the drugs listed in our PDL as long as they are medically necessary and appropriate. All Health Choice member prescriptions must be filled at a Health Choice Arizona network pharmacy, and other plan rules must be followed.